Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of CPT2-knockdown HCT116 colorectal cancer cells

ABSTRACT: CPT2 knockdown induced accumulation of glycerophospholipids and promoted CRC progression. We conducted transcriptomic sequencing of CPT2-knockdown HCT116 CRC cells to explore the underlying mechanism.

ORGANISM(S): Homo sapiens

PROVIDER: GSE303954 | GEO | 2025/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profile of CPT2-knockdown HCT116 colorectal cancer cells

Project description:Gene expression profile of CPT2-knockdown HCT116 colorectal cancer cells

| PRJNA1298307 | ENA

CPT2 inhibition activates selective autophagy by enhancing glycerophospholipid biosynthesis in colorectal cancer

Project description:<p>Metabolic reprogramming is one of the hallmark events in colorectal cancer (CRC).  Tumor cells adapt to microenvironmental changes by regulating energy and biomaterial metabolism. This study identified abnormal lipid accumulation and significant downregulation of fatty acid metabolism in CRC. The core gene of this pathway, CPT2, critically impacts CRC patient survival and regulates tumor cell proliferation both in vitro and in vivo. Metabolite analysis demonstrated that CPT2 knockdown induced accumulation of glycerophospholipids (GPs), primarily phosphatidylcholine (PC) and phosphatidylethanolamine (PE), driven by enhanced long-chain fatty acid (LCFA)-dependent GP biosynthesis mediated by GPAT4. Transcriptomic analysis and subsequent experiments revealed that GP accumulation, as key components of vesicles and autophagosomes, promoted autophagosome maturation and elongation, thereby activating selective autophagy (lipophagy) in CRC cells and accelerating tumor progression. These findings enhance understanding of tumor metabolic characteristics and identify novel diagnostic and therapeutic targets for CRC.</p>

2025-09-01 | MTBLS12783 | MetaboLights

Analysis of DNA methylation in TET1 depleted colorectal cancer HCT116 cells

Project description:We aimed to analyze the relationship between TET1 and aberrant CpG methylation in colorectal cancer (CRC). We established two stable TET1 knockdown clones and negative control clones of HCT116 cells, and carried out DNA methylation analysis with HumanMethylation450 BeadChip.

2017-01-01 | GSE84399 | GEO

Analysis of gene expression in TET1 depleted colorectal cancer HCT116 cells

Project description:We aimed to analyze the relationship between TET1 and aberrant CpG methylation in colorectal cancer (CRC). We established two stable TET1 knockdown clones and negative control clones of HCT116 cells, and carried out gene expression analysis with Agilent Human Gene Expression microarray kit.

2017-01-01 | GSE84398 | GEO

BORIS knockdown in colorectal cancer cells HCT116 and Caco-2

Project description:BORIS expresses abnormally in colorectal cancer cells. Both the expression and the copy number of BORIS are remarkably higher in colorectal cancer cells than in normal colon or rectal cells. BORIS is potential diagnosis, prognosis or therapeutic target for colorectal cancer. To expand our view of the signaling pathway related with BORIS, altered gene expression by BORIS knockdown was assessed by microarray assay. To study the gene regulation by BORIS knockdown, microarray assay was applied to screen the gene expression regulated by BORIS siRNA in colorectal cancer cells HCT116 and Caco-2

2018-07-01 | GSE86172 | GEO

Expression data from HCT116 cells following H19 knockdown

Project description:Knockdown of H19 leads to cell cycle arrest, reduced cell proliferation, and reduced cell migration in HCT116 cells. We used microarrays to detail the global programme of gene expression following H19 knockdown in HCT116 cells

2016-09-29 | GSE87430 | GEO

mRNA-seq of HCT116 USP22 knockdown cells

Project description:This analysis identifies genes which are affected in HCT116 cells upon USP22 knockdown

2019-10-26 | E-MTAB-7393 | biostudies-arrayexpress

mRNA-seq of HCT116 USP22 knockdown cells

Project description:mRNA-seq of HCT116 USP22 knockdown cells

| PRJEB29794 | ENA

Expression signature in a human colorectal cancer cell line HCT116 transfected with miR-1 precursor molecule

Project description:We identified that miR-1 is silenced in association with CpG island hypermethylation in a colorectal cancer (CRC) cell line, HCT116. To determine whether miR-1 serves as a tumor suppressor in CRC, we transfected CRC cell lines with a miR-1 precursor molecule or a negative control, and carried then out a series of MTT assays. Forty-eight hours after transfection, we observed that ectopic expression of miR-1 moderately suppressed growth in all three cell lines. To further clarify the effect of the miRNA, we next performed gene expression microarray analysis in HCT116 cells transfected with a miR-1 precursor molecule or a negative control. We found that 2769 probe sets were downregulated (> 1.5-fold) by ectopic miR-1 expression, and gene ontology analysis revealed that “extracellular regions”, “membrane” and “response to wound healing” genes were significantly enriched among the downregulated genes. HCT116 cells were transfected with a Pre-miR-1 miRNA Precursor Molecule (Ambion) or Pre-miR miRNA Molecules Negative Control #1 (Ambion). Forty-eight hours after transfection, total RNA extraction were carried out, and gene expression signatures were analyzed.

2011-07-01 | E-GEOD-29760 | biostudies-arrayexpress

Gene expression profile of colorectal cancer cell Caco-2 after OCC-1 knockdown

Project description:OCC-1 is one of the earliest annotated long noncoding RNAs (lncRNAs) in colorectal cancer (CRC). In our study, we found that knockdown of OCC-1 by shRNAs promotes CRC cell growth both in vitro and in vivo. To gain insight into the molecular function of OCC-1, we profiled the gene expression of Caco-2 cells after OCC-1 knockdown by microarray.

2018-03-11 | GSE108816 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data